Atara Biotherapeutics (ATRA) Lifted to Buy at BidaskClub

Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.

A number of other analysts also recently issued reports on ATRA. Jefferies Group reissued a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research report on Thursday, October 5th. Goldman Sachs Group reissued a “neutral” rating and issued a $20.00 target price on shares of Atara Biotherapeutics in a research report on Friday, October 6th. Canaccord Genuity reissued a “buy” rating on shares of Atara Biotherapeutics in a research report on Thursday, November 9th. ValuEngine raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Finally, Citigroup raised Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 target price for the company in a research report on Wednesday, January 3rd. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $26.00.

Shares of Atara Biotherapeutics (ATRA) opened at $20.70 on Thursday. Atara Biotherapeutics has a 52-week low of $11.80 and a 52-week high of $23.00. The stock has a market capitalization of $633.33, a price-to-earnings ratio of -5.97 and a beta of 1.27.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.05). analysts anticipate that Atara Biotherapeutics will post -4 EPS for the current fiscal year.

In other news, CEO Isaac E. Ciechanover sold 2,200 shares of Atara Biotherapeutics stock in a transaction on Friday, December 28th. The stock was sold at an average price of $15.15, for a total value of $33,330.00. Following the completion of the transaction, the chief executive officer now directly owns 743,675 shares in the company, valued at $11,266,676.25. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock in a transaction on Monday, October 16th. The shares were sold at an average price of $14.35, for a total value of $86,100.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 121,788 shares of company stock valued at $2,194,934. 16.20% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its position in shares of Atara Biotherapeutics by 2.9% in the second quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock valued at $304,000 after purchasing an additional 610 shares in the last quarter. Teachers Advisors LLC grew its position in shares of Atara Biotherapeutics by 2.4% in the second quarter. Teachers Advisors LLC now owns 47,156 shares of the biotechnology company’s stock valued at $660,000 after purchasing an additional 1,110 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Atara Biotherapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after purchasing an additional 1,369 shares in the last quarter. Voya Investment Management LLC grew its position in shares of Atara Biotherapeutics by 16.2% in the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 1,651 shares in the last quarter. Finally, Rhumbline Advisers grew its position in shares of Atara Biotherapeutics by 11.3% in the second quarter. Rhumbline Advisers now owns 31,373 shares of the biotechnology company’s stock valued at $439,000 after purchasing an additional 3,175 shares in the last quarter. Institutional investors own 85.61% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.themarketsdaily.com/2018/01/11/atara-biotherapeutics-atra-lifted-to-buy-at-bidaskclub.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply